PharmaView   NOV.2006

Pharmaceutical Marketers are facing increasing pressures: increasing competition; squeezed margins; shrinking budgets; more to do and less time to do it. It’s becoming difficult to work any harder, and of course it's always better to work smarter. Therefore we bring you the PharmaView.

PharmaView is a biweekly educational and informative newsletter for improving readers’ marketing knowledge and reporting the latest news in the pharma industry. It also provides great opportunities to exchange ideas, network and be recognized among your peers in the industry.

Through PharmaView, you can:

Learn peer’s experience in pharma marketing

Stay in touch with what’s happening in pharmaceutical marketing today

Be on the pioneering edge of pharmaceutical marketing

Have networking / idea exchange opportunities

About Us 

Integrating local knowledge with international perspective, Consultech Co. Ltd. offers its clients and prospects one-lstop solutions with sales and marketing consultancy, advertising and promotion strategies.

Idenix Pharmaceuticals, Inc. today announced the approval of TYZEKA(TM) (telbivudine) by the U.S. Food and Drug Administration (FDA) as a new once-la-day oral treatment, taken with or without food, for patients with chronic hepatitis B (CHB).

Oct. 25, 2006

Avanir Pharmaceuticals announced that it has received an approvable letter from the U.S. Food and Drug Administration (FDA) for Zenvia (formerly referred to as Neurodex) for the treatment of involuntary emotional expression disorder ("IEED").

Oct. 31, 2006

Alpharma Inc., a global specialty pharmaceutical company, today announced that it has been notified by United States Food and Drug Administration ("FDA") that its pending application for KADIAN(R) 80mg capsule has received approval.

Oct. 30, 2006

As the pharmaceutical industry looks for new and more effective approaches to sales and marketing, Baba Awopetu, International Brand Manager at Stryker, suggests that it rethink its approaches to targeting and segmentation.

Oct. 26, 2006

What is the Real Impact of DTC Advertising on the Physician-Patient Dialogue?

Over the past several years, the impact of DTC on the physician-patient interaction – and on the quality of health care – has been hotly debated. Supporters of DTC advertising believe it is a major source for public education about a wide variety of symptoms and health conditions.

Oct. 21, 2006

Pharmaceutical marketing: just what the doctor ordered?

Clear, accurate and comprehensive information should be readily and easy available. But is DTC advertising the best remedy?

AstraZeneca's Pipeline Breakdown

Shares of AstraZeneca fell $5.13, or 7.7%, to $61.24 Thursday morning after the British drugmaker announced highly disappointing clinical trial data for NXY-059, an experimental treatment for stroke patients.

Oct 26, 2006

Eisai Introduces Rx-to-OTC Switch Product For Allergy-related Rhinitis And Skin Problems

Eisai has introduced a Rx-to-OTC switch product for allergic-related rhinitis and skin problems, available from November 1.

Nov 01, 2006

CDC to subsidize Merck's cervical cancer vaccine

U.S. health authorities added Merck & Co. Inc.'s new vaccine for cervical cancer to a government-subsidized vaccine program for schoolchildren, helping to expand its availability, the company said on Wednesday.

Nov 01, 2006

Inside Merck's Biotech Buy

Here's how fast the world of multibillion-dollar pharmaceutical companies can move. A week ago, Howard Robin, chief executive of tiny San Francisco-based biotechnology firm Sirna Therapeutics, told this reporter to expect an announcement sometime soon of another collaboration with a big pharmaceutical company on one of Sirna's drug candidates.

Oct 31, 2006

Please feel free to offer your opinions and advices about PharmaView in order to better our services. Should you have any comments, or if you want to unsubscribe  from PharmaView, please send us an email: pharmaview@Consultech.com.cn  . Thank you!